Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 6/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23391280 | 1.00 | MEN1 (0.40) | MEN1KMT2ANPSR1SRCHSD17B10 | |
| SCHEMBL16553631 | 0.88 | MEN1 (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL790348 | 0.88 | BTN3A1 (0.50) | KMT2ABTN3A1ELANE | |
| SCHEMBL23391220 | 0.86 | ALDH1A1 (0.52) | MEN1KMT2ANPSR1HSD17B10ALDH1A1 | |
| SCHEMBL23391219 | 0.86 | ALDH1A1 (0.52) | MEN1KMT2ANPSR1HSD17B10ALDH1A1 | |
| SCHEMBL15052723 | 0.85 | BTN3A1 (0.52) | BTN3A1ELANE | |
| SCHEMBL784413 | 0.85 | BTN3A1 (0.52) | BTN3A1ELANE | |
| SCHEMBL17198445 | 0.85 | BTN3A1 (0.52) | BTN3A1ELANE | |
| SCHEMBL20773105 | 0.84 | ANPEP (0.44) | MEN1KMT2ANPSR1SRCHSD17B10 | |
| SCHEMBL4971442 | 0.84 | ANPEP (0.44) | MEN1KMT2ANPSR1SRCHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-3831388-B1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FOR USE IN SUPPRESSING ADENOVIRUS | FUJIFILM CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4107164-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3831388-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20210155644-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-05-27 | — | — | US | disclosed |
| EP-3252066-B1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2019-05-22 | — | — | EP | disclosed |
| US-9481703-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| EP-3057976-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-08-24 | — | — | EP | disclosed |
| EP-3041855-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-07-13 | — | — | EP | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
| EP-2794630-A1 | SUBSTITUTED PHOSPHOROTHIOATE NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014164533-A1 | METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2013096680-A1 | SUBSTITUTED PHOSPHOROTHIOATE NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | MEN1 3636/4885KMT2A 3822/4885NPSR1 1383/4885 |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | MEN1 4879/4885KMT2A 2713/4885NPSR1 2739/4885 |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | MEN1 3636/4885KMT2A 3822/4885NPSR1 1383/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | MEN1 3636/4885KMT2A 3822/4885NPSR1 1383/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | MEN1 3636/4885KMT2A 3822/4885NPSR1 1383/4885 |
| US-20210155644-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, NOX1 | MEN1 2904/4885KMT2A 4547/4885NPSR1 2432/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | MEN1 4879/4885KMT2A 2713/4885NPSR1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.